Pazopanib in the treatment of advanced renal cell carcinoma

• Published in: Медицинский совет
• Main Authors: M. I. Volkova, A. S. Olshanskaya
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2018-11-01
• Subjects: pazopanib; sorafenib; sunitinib; axitinib; bevacizumab; everolimus; disseminated renal cell carcinoma; targeted therapy; survival
• Online Access: https://www.med-sovet.pro/jour/article/view/2753

Pazopanib is an oral multitargeted tyrozine kinase inhibitor that is used in advanced renal cancer in most countries of the world. Pazopanib inhibits tyrosine kinase receptors involved in tumor angiogenesis and proliferation, including VEGF, platelet-derived growth factor (PDGF) and stem cell growth factor receptor c-Kit, which leads to inhibiting angiogenesis, growth and proliferation of tumor cells. In clinical trials, pazopanib demonstrated improvement of progression-free survival (PFS) versus placebo in previously untreated patients and patients treated with cytokines, as well as the absence of worsening PFS versus sunitinib in the first-line therapy of clear cell RCC in the good- and intermediate prognosis groups. In addition, pazopanib demonstrated a better safety profile than sunitinib. The results of use of pazopanib in broad clinical practice are consistent with data from randomized trials that confirms the high efficacy combined with good tolerability of this drug even in patients who do not meet the generally accepted criteria for the inclusion in clinical trials.